ImmunoGen, Inc.
IMGN

$8.73 B
Marketcap
$31.24
Share price
Country
$0.01
Change (1 day)
$31.25
Year High
$3.61
Year Low
Categories

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

marketcap

Stock price history for ImmunoGen, Inc. (IMGN)

Highest end of day price: $43.81 USD on 2000-11-08

Lowest end of day price: $0.84 USD on 1997-12-31

Stock price history of ImmunoGen, Inc. from 1989 to 2024